Symptoms and quality of life improvement in heart failure patients with reduced LVEF taking ivabradine - 06/01/20
Résumé |
Background |
Despide advances in the treatment of heart failure with reduced LVEF, rates of hospitalization and mortality remain relatively high. With the discovery of If channels and ivabradine, an approach of slowing heart rate not related to betablockers became possible.
Purpose |
The main objective of this study is to report symptoms and quality of life improvement in heart failure patients with reduced LVEF taking ivabradine.
Methods |
A prospective and descriptive study was lead during a period of 3 months (from November 2017 to January 2018), including heart failure patients with LVEF of less than 35%, in sinus rhythm and a heart rate of more than 70 bpm and still symptomatic class III to IV NYHA despide an optimal medical therapy including a betablocker, an angiotensin renin system antagonist and a mineralocorticoid receptor antagonist for at least 3 months. Statistical analysis was performed using the SPSS 2.0 software.
Results |
Thirty-tree patients were collected. Regarding symptoms, relief of angina was obtained in 87.9%, 72.7% of patients were brought to class II NYHA and 12.1% to class I NYHA. Also, slowing heart rate under 70 bpm was possible in 69.7% of patients. Ischemic aetiology was the most represented (69.7%). 81.8% of patients were taking the dose of 10mg of ivabradine.
Conclusion |
Ivabradine reduces hospitalization and mortality rates in patients with heart failure and LVEF of less than 35%, in sinus rhythm and a heart rate of more than 70 bpm.
Le texte complet de cet article est disponible en PDF.Plan
Vol 12 - N° 1
P. 51 - janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.